Product Information

TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE) is a generic product labeled by Ascend Laboratories, LLC, priced at $0.1256 per EA under NDC 67877027801. Its NADAC has been published 296 times since Dec 23, 2020.

FDA first approved this application on Nov 12, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE)

Tacrolimus
$0.1256per EA

Strength

.5 mg/1

NDC

67877027801

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

TACROLIMUS

Approval Type

Generic (ANDA)

FDA Application

ANDA203740

FDA Approved

11/12/2020

TE Code

AB

On Market Since

11/13/2020

Pharmacological Classes

Price Statistics

The NADAC for TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE) has been published 296 times since Dec 23, 2020, and over the history we have for it it has declined 79.7%. The table below summarizes its recorded NADAC range and movement.

Current price$0.1256 per EA
All-time high$0.6185 (Jan 13, 2021)
All-time low$0.1091 (Nov 20, 2024)
52-week high$0.1744
52-week low$0.1256
Median price$0.1833
Average price$0.2155
Largest weekly change+49.0% (Jun 19, 2024)
Weeks tracked296
Tracking sinceDec 23, 2020

Price History

1W

-3.1%

1M

-3.1%

3M

-14.3%

6M

-16.4%

1Y

-25.7%

3Y

-30.6%

5Y

-59.8%

All

-79.7%

Generic Alternatives

The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE)?

The current National Average Drug Acquisition Cost (NADAC) for TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE), manufactured by Ascend Laboratories, LLC, is $0.1256 per EA (NDC 67877027801), effective Aug 19, 2026.

How has the price of TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE) changed over time?

Over the history we have for it, the NADAC for TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE) has declined 79.7%. It has been tracked across 296 weekly CMS publications since Dec 23, 2020.

What are the highest and lowest recorded NADAC prices for TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE)?

Since Dec 23, 2020, the NADAC for TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE) has ranged from a low of $0.1091 (Nov 20, 2024) to a high of $0.6185 (Jan 13, 2021), with a median of $0.1833 per EA.

Are there cheaper alternatives to TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE)?

12 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE) in a comparable dosage form, but none are currently priced below it.

Who manufactures TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE)?

TACROLIMUS 0.5 MG CAPSULE (IMMEDIATE RELEASE) (NDC 67877027801) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.